Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
about
Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisParadoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overviewLong-term safety and efficacy of infliximab for the treatment of ankylosing spondylitisPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesRedeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel diseaseLong-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy.Infliximab: 12 years of experienceManagement of arthropathy in inflammatory bowel diseases.Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysisEtanercept in the treatment of recalcitrant enteropathic arthritis: a case report.Management and evaluation of extra-articular manifestations in spondyloarthritisTumour necrosis factor inhibitors in ankylosing spondylitis.Developments in the scientific and clinical understanding of the spondyloarthritidesUpdate on the use of etanercept across a spectrum of rheumatoid disorders.Musculoskeletal manifestations of inflammatory bowel disease.A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.Joint involvement in inflammatory bowel disease: managing inflammation outside the digestive system.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.Colitis associated with biological agentsParadoxical effects of anti-TNF-α agents in inflammatory diseases.Biological therapies for spondyloarthritis.Secukinumab (AIN457) in the treatment of ankylosing spondylitis.Management of ankylosing spondylitis with infliximab.Efficacy and safety of adalimumab in ankylosing spondylitis.Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases.Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.TNFalpha blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats.Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies.Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study.Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis.Evidence for the prevention of enthesitis in HLA-B27/hβ(2)m transgenic rats treated with a monoclonal antibody against TNF-α.Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis.Inflammatory bowel disease-associated spondyloarthropathies.Recommendations for the management and treatment of ankylosing spondylitis.Crohn's disease diagnosis during adalimumab treatment.
P2860
Q22241416-927AF1B7-45D5-4652-A354-0720FD41752EQ24603648-09600BAE-873D-46B7-B1F9-7F8F401362F0Q26738918-85985ABB-EFC3-4D06-B22F-E3FB7F5F74D8Q26774173-4B580E0B-2706-47EC-810D-977F3D331642Q26777084-18EF9EDB-AEEB-4AED-ACFB-78125394C836Q27027630-A436CABD-6817-4A37-BEE3-8BC4894DAFC8Q33766318-47F97EAD-1630-4FB6-9367-B31C29ED334DQ34449888-0B937545-CC03-4BF3-B02D-79E31618BF75Q35070446-C70A26DE-3DEA-41BB-9AC6-E3EE593A2044Q35091366-DB2F9236-EF42-4961-AB98-ECBADA8844F9Q35608168-41A48A4C-B147-4260-B29F-63DD5AED5408Q36099077-49AED438-48CE-45B5-83B0-1354A78C5475Q36439889-BBCF4892-1CCC-483B-80EB-4F771BF56DE2Q37142118-A5A58A66-66B1-4A7B-8A08-EA48331459C2Q37207018-BABEC516-8D09-4822-9802-DE12E718F65EQ37290628-8E7D756D-7516-480D-A984-E8CA09FF0953Q37466458-E9AE023A-3E54-4502-88D3-8C8F955C691AQ37621044-22416245-B15B-47AC-87BD-3A28F52DC724Q37688137-A1117D16-4C65-492C-B151-6B66865562A5Q37729028-A96EB99F-6AAF-4159-BFF0-49D58ADF31FFQ37994661-D4F06347-13C2-4137-9036-2E4AB23359F6Q38007938-940370EE-E4B7-4C5F-8E07-C63B5D90A7BCQ38170158-6FBB75B7-5E75-4504-9E8D-6872E022D01BQ38217223-740BD9EC-A80B-46CD-B59D-19E4A8A204A1Q38777116-920B0A66-84AF-42C1-BADB-1A279B359FE9Q38993236-AD8D57D0-E3D6-4055-B89C-1881C38E2AAFQ38993324-95ED5D30-0C26-42A6-80CE-B113D2CBB570Q39453926-6879D6F2-5005-418D-A5B5-B6ACF257CC12Q40179378-0E1102D5-0762-416B-A0CB-59ACB9D8DB87Q40318692-22B0779B-5617-4F37-8F18-AB7D49FD52A9Q41807889-9F02885B-D255-4D44-863A-58C70256CB49Q41861964-DE894A86-8FC0-4405-BA26-74603D82207BQ42126037-CE183A82-9375-4C3E-9FCE-B2828FD37BAAQ42377151-745C9EC6-7DD7-4F96-AD38-C772CBF684B8Q42625894-8ECEE049-5E88-4956-9312-823C7440FFB2Q42914686-3C0E3F81-BBB9-4D29-BA07-CA98E49B7BDAQ43066415-D275DFBB-D3B8-46ED-841B-7EECC329A219Q43122153-4761BF0F-6B7F-4189-BE81-53EC7E40E369Q44898441-00F810DE-DAB2-45EE-B1BB-186A534C37D9Q45050734-0C983E89-20C8-4CE9-8AE1-93689BFF114A
P2860
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Differences in the incidence o ...... necrosis factor alpha agents.
@ast
Differences in the incidence o ...... necrosis factor alpha agents.
@en
type
label
Differences in the incidence o ...... necrosis factor alpha agents.
@ast
Differences in the incidence o ...... necrosis factor alpha agents.
@en
prefLabel
Differences in the incidence o ...... necrosis factor alpha agents.
@ast
Differences in the incidence o ...... necrosis factor alpha agents.
@en
P2093
P356
P1476
Differences in the incidence o ...... necrosis factor alpha agents.
@en
P2093
M Rudwaleit
X Baraliakos
P304
P356
10.1002/ART.22669
P577
2007-05-01T00:00:00Z